Proprietary COVID-19 and Vaccine thread

[GhostOfMatchesMalone]

Doctors and lawyers don’t get to make this call. The law is set, EUA at first, and now the PREP act provide blanket immunity for vax manufacturers.

Which is why you’ll probably see the vaccines pulled after the PREP act expires.

Amazing how many people happily injected an unapproved substance into their arms, just cause their politics told them to.

 

[GhostOfMatchesMalone]

MDFer online poker night with the boyz . 😂

That monkey has an internet Tesla and an internet boat called Big Suck. You just know it.

 

[fatman76]

Amazing how many people happily injected an unapproved substance into their arms, just cause their politics told them to.

It's not just unapproved, but if something does go wrong you're on you own to deal with the repercussions.

A radiologist friend of mine will be using a walker for the rest of his life.

 

[GhostOfMatchesMalone]

It's not just unapproved, but if something does go wrong you're on you own to deal with the repercussions.

A radiologist friend of mine will be using a walker for the rest of his life.

I honestly thought that would be the wakeup call for the sheep. I get some people deciding to take the shots early on before we had good intel on the dangers. I get that. But after the dangers and risks became known, I was stunned that sheep not only pressed forward with taking the shots, but DOUBLED DOWN on taking them. It was like they were saying 'This might kill me, but it will keep my politics alive, and that's more important'.

Pure insanity. Unrelated: Wellness check - @Uniformed_ReRe @gator1776 @G8trDad3

 

[Mdfgator]

It's not just unapproved, but if something does go wrong you're on you own to deal with the repercussions.

A radiologist friend of mine will be using a walker for the rest of his life.

How much does he weigh?

 

[gatordad3]

He's just as queer as Jimmy Kimmel.

The Late Show Shut Down Last Week as Ultra-Vaxxed Stephen Colbert Dealt With Third Round of Covid | The Gateway Pundit | by Mike LaChance

Stephen Colbert is so jazzed about Covid vaccines that he did a cringeworthy song and dance about them but it doesn’t look like they have done him much good.

www.thegatewaypundit.com

 

[nail1988]

😂😂

 

[nail1988]

Sheep 🐑

 

[gatordad3]

So I guess what's his name will have no other choice to discuss the jab here now that a certain thread is locked.

My daughter happens to be a Taylor Swift fan, so is BSC/MDF.

 

[gatordad3]

😂😂

View embedded media

 

[gatordad3]

 

[nail1988]

SHEEPLE

 

[fatman76]

SHEEPLE

View embedded media

Covid response had zero to do with health...

 

[nail1988]

 

[nail1988]

What’s this?

 

[nail1988]

@instaGATOR

 

[nail1988]

 

[nail1988]

Sheeple

 

[nail1988]

 

[gatordad3]

Science, is what it is:
Works: Tocilizumab, (IL-6 monoclonal antibody), Dexamethasone, Remdesivir
Doesn't work: Hydroxychloroquine, convalescent plasma, Ivermectin
In addition, Remdesivir has also been show to lower mortality in moderate to severe cases by roughly 6%.


In patients hospitalized with COVID-19, hypoxemia, and systemic inflammation, treatment with tocilizumab was associated with a reduced 28-day mortality. Tocilizumab, an anti-IL-6 receptor monoclonal antibody, inhibits binding of IL-6 to its receptors, thereby blocking IL-6 signaling and decreasing inflammation. Early in the COVID-19 pandemic, it became evident that some patients with COVID-19 developed an acute hyperinflammatory syndrome characterized by elevations in proinflammatory cytokines and multiorgan failure. Although data were lacking, tocilizumab was used with the intent to mitigate this hyperinflammatory syndrome.


There have now been several randomized controlled trials (RCTs) investigating the role of tocilizumab in the treatment of COVID-19. Two of these RCTs, RECOVERY and REMAP-CAP, reported improved outcomes with tocilizumab in patients who were critically ill. Both trials permitted patients to be receiving mechanical ventilation at time of random assignment, and both initiated tocilizumab early in the hospital and ICU course. Taken together, these studies suggest that tocilizumab may be of greatest benefit when administered early and in patients with an inflammatory phenotype and rapidly progressive disease.

RECOVERY, the largest of these RCTs, enrolled 4,116 adults with hypoxia and evidence of systemic inflammation, defined by a C-reactive protein level ≥7.5 mg/dL (75 mg/L). Of the 2,022 adults randomly assigned to tocilizumab, 268 were receiving invasive mechanical ventilation and 819 were receiving noninvasive mechanical ventilation (high-flow nasal cannula, CPAP) at the time of random assignment. Glucocorticoid use was equal across both arms of the trial, with 82% of participants receiving dexamethasone, after data demonstrated it reduced mortality in COVID-19. Treatment with tocilizumab was associated with decreased 28-day mortality (31% vs 35%; RR, 0.85; 95% CI, 0.76-0.94; P = .0028). These findings were consistent in prespecified subgroup analysis, including those receiving glucocorticoids (29% vs 35%; RR, 0.79; 95% CI, 0.70-0.89), invasive mechanical ventilation at the time of random assignment (49% vs 51%; RR, 0.93; 95% CI, 0.74-1.18), and noninvasive mechanical ventilation (38% vs 42%; RR, 0.86; 95% CI, 0.74-1.00) (choice D is correct).

Patients critically ill with COVID-19 are at increased risk for thrombosis even when treated with standard-dose pharmacologic thromboprophylaxis. Furthermore, elevated biomarkers of thrombosis, such as D-dimer, are independently associated with greater risk of thrombosis, disease progression, and higher mortality in patients with COVID-19. However, therapeutic-dose anticoagulation with heparin has not been shown to decrease mortality in patients critically ill with COVID-19 (choice C is incorrect). An adaptive, multiplatform RCT in patients critically ill with COVID-19 randomly assigned 534 patients to therapeutic-dose anticoagulation and 564 patients to thromboprophylaxis (REMAP-CAP, ACTIV-4a, and ATTACC trials). Patients included in this trial required ICU-level respiratory or cardiovascular support, including high-flow nasal cannula, noninvasive or invasive mechanical ventilation, extracorporeal life support, vasopressors, or inotropes. In this trial, treatment with therapeutic-dose anticoagulation did not decrease in-hospital mortality, and results suggest probable harm with its use. Thus, empiric therapeutic-dose anticoagulation is not recommended in patients critically ill with COVID-19.

Neither convalescent plasma nor hydroxychloroquine has been shown to reduce mortality in patients hospitalized with COVID-19 (choices A and B are incorrect). RCTs of hydroxychloroquine showed a trend toward increased mortality in patients hospitalized with COVID-19 (RR, 1.08; 95% CI, 0.99-1.19).

 

[gatordad3]

 

[GhostOfMatchesMalone]

 

[nail1988]

Think of all the military folks these dumb bastards punished and forced out of the service? Idiots

 

[NavigatorII]

Think of all the military folks these dumb bastards punished and forced out of the service? Idiots

View embedded media

Just saw this on GP. Who knew that would be a horrible idea? IDIOTS!!!

 

[nail1988]

Fraudci needs to spend the rest of his life in Leavenworth

 

[Gator Fever]

Think of all the military folks these dumb bastards punished and forced out of the service? Idiots

View embedded media

If Trump wins all those discharges need to be upgraded to Honorable and anyone wanting to rejoin should be allowed to.

 

[GhostOfMatchesMalone]

Fraudci needs to spend the rest of his life in Leavenworth

View embedded media

cc @Uniformed_ReRe @gator1776 @goldmom I'm old enough to remember when other posters here said the same thing, and a certain internet doctor shouted us down, and two of his cheerleaders furiously shook their clot shot pom poms in our faces till we changed the topic.

 

[gatordad3]

If any of you are wondering, I took this quote from a thread that ends up just like every thread that MDF starts, with no replies.

Science, is what it is:
Works: Tocilizumab, (IL-6 monoclonal antibody), Dexamethasone, Remdesivir
Doesn't work: Hydroxychloroquine, convalescent plasma, Ivermectin
In addition, Remdesivir has also been show to lower mortality in moderate to severe cases by roughly 6%.


In patients hospitalized with COVID-19, hypoxemia, and systemic inflammation, treatment with tocilizumab was associated with a reduced 28-day mortality. Tocilizumab, an anti-IL-6 receptor monoclonal antibody, inhibits binding of IL-6 to its receptors, thereby blocking IL-6 signaling and decreasing inflammation. Early in the COVID-19 pandemic, it became evident that some patients with COVID-19 developed an acute hyperinflammatory syndrome characterized by elevations in proinflammatory cytokines and multiorgan failure. Although data were lacking, tocilizumab was used with the intent to mitigate this hyperinflammatory syndrome.


There have now been several randomized controlled trials (RCTs) investigating the role of tocilizumab in the treatment of COVID-19. Two of these RCTs, RECOVERY and REMAP-CAP, reported improved outcomes with tocilizumab in patients who were critically ill. Both trials permitted patients to be receiving mechanical ventilation at time of random assignment, and both initiated tocilizumab early in the hospital and ICU course. Taken together, these studies suggest that tocilizumab may be of greatest benefit when administered early and in patients with an inflammatory phenotype and rapidly progressive disease.

RECOVERY, the largest of these RCTs, enrolled 4,116 adults with hypoxia and evidence of systemic inflammation, defined by a C-reactive protein level ≥7.5 mg/dL (75 mg/L). Of the 2,022 adults randomly assigned to tocilizumab, 268 were receiving invasive mechanical ventilation and 819 were receiving noninvasive mechanical ventilation (high-flow nasal cannula, CPAP) at the time of random assignment. Glucocorticoid use was equal across both arms of the trial, with 82% of participants receiving dexamethasone, after data demonstrated it reduced mortality in COVID-19. Treatment with tocilizumab was associated with decreased 28-day mortality (31% vs 35%; RR, 0.85; 95% CI, 0.76-0.94; P = .0028). These findings were consistent in prespecified subgroup analysis, including those receiving glucocorticoids (29% vs 35%; RR, 0.79; 95% CI, 0.70-0.89), invasive mechanical ventilation at the time of random assignment (49% vs 51%; RR, 0.93; 95% CI, 0.74-1.18), and noninvasive mechanical ventilation (38% vs 42%; RR, 0.86; 95% CI, 0.74-1.00) (choice D is correct).

Patients critically ill with COVID-19 are at increased risk for thrombosis even when treated with standard-dose pharmacologic thromboprophylaxis. Furthermore, elevated biomarkers of thrombosis, such as D-dimer, are independently associated with greater risk of thrombosis, disease progression, and higher mortality in patients with COVID-19. However, therapeutic-dose anticoagulation with heparin has not been shown to decrease mortality in patients critically ill with COVID-19 (choice C is incorrect). An adaptive, multiplatform RCT in patients critically ill with COVID-19 randomly assigned 534 patients to therapeutic-dose anticoagulation and 564 patients to thromboprophylaxis (REMAP-CAP, ACTIV-4a, and ATTACC trials). Patients included in this trial required ICU-level respiratory or cardiovascular support, including high-flow nasal cannula, noninvasive or invasive mechanical ventilation, extracorporeal life support, vasopressors, or inotropes. In this trial, treatment with therapeutic-dose anticoagulation did not decrease in-hospital mortality, and results suggest probable harm with its use. Thus, empiric therapeutic-dose anticoagulation is not recommended in patients critically ill with COVID-19.

Neither convalescent plasma nor hydroxychloroquine has been shown to reduce mortality in patients hospitalized with COVID-19 (choices A and B are incorrect). RCTs of hydroxychloroquine showed a trend toward increased mortality in patients hospitalized with COVID-19 (RR, 1.08; 95% CI, 0.99-1.19).

 

[nail1988]

 

[BamaFan1137]

If any of you are wondering, I took this quote from a thread that ends up just like every thread that MDF starts, with no replies.

So you're saying that many women lie about how many times they have been jabbed?

😂

 

[nail1988]

 

[nail1988]

 

[GhostOfMatchesMalone]

If any of you are wondering, I took this quote from a thread that ends up just like every thread that MDF starts, with no replies.

Wait, @gator1776 claims that ivermectin doesn't treat covid?



I'm honestly stunned he hasn't been banned from this board years ago. I get the mods want to avoid the dreaded 'echo chamber', but goodness. At what cost?

 

[nail1988]

What’s this?

 

[fatman76]

What’s this?

View embedded media

It's how people act when you lie to them for profit.

 

[fatman76]

Wait, @gator1776 claims that ivermectin doesn't treat covid?

View embedded media

I'm honestly stunned he hasn't been banned from this board years ago. I get the mods want to avoid the dreaded 'echo chamber', but goodness. At what cost?

We're running out of conspiracy theories...

But this makes total sense. The EUA REQUIRES that there is no available alternative treatment.

If Big Govt and Big Pharma wanted to keep the money flowing to them, they were forced to make sure no other treatment saw the light of day. Every study commissioned on IVM and HCQ were intentionally designed to show those drugs carried no benefit, and in some cases harm.

It's the same cash-infused perversion of science we see with global warming.

Anyone who tells you to "follow the science" needs to "follow the money" first.

 

[nail1988]

Yes sir 😎😎😎

 

[NavigatorII]

 

[gatordad3]

Looks as if Kelce sold his soul. He's boning a pedo, in Bud Light and Phizer commercials. The refs made sure the Chefs won last seasons super bowl. He then whines like a bitch during a post game interview.

 

[Gator Fever]